Perspective introduces ‘pre-targeting’ Theranostic Technology Platform

Perspective Therapeutics announced that it has executed an exclusive license agreement with Stony Brook University for the rights to its Cuburbit(7)uril-admantane pre-targeting platform and was awarded the Phase I tranche of a 2.5-year, Fastrack Small Business Innovation Research grant from the National Institutes of Health, NIH, National Cancer Institute in support of Perspective’s CB7-Adma host-guest pre-targeting program for the diagnosis and treatment of cancer. “By embracing a strategy that leverages the precision of monoclonal antibodies and the versatility of small molecules, Perspective has the opportunity to expand the therapeutic options available to patients receiving radiation therapy,” said Thijs Spoor, Chief Executive Officer at Perspective Therapeutics. The exclusive license with Stony Brook University covers the global intellectual property rights for the CB7-Adma pre-targeting platform.